Christopher J. Dinsmore
Research Subjects
Christopher J. Dinsmore has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Wesley Trotter
Kronos Bio, Cambridge, Massachusetts
42 shared publications - Charles Y. Lin
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
42 shared publications - Giulia Giorgetti
Clinic of Hematology, Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa, Genoa, Italy
42 shared publications - Hua Gao
Kronos Bio, Cambridge, Massachusetts
42 shared publications - Jessica Encinas Mayoral
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., United States
42 shared publications - Jun Li
Kronos Bio, Cambridge, Massachusetts
42 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
TRN mapping integrates multiple types of data to identify candidate TF-cofactor relationships.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
TRN mapping integrates multiple types of data to identify candidate TF-cofactor relationships.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
MM cells undergo cell cycle arrest, followed by induction of apoptosis, in response to KB528 treatment.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
MM cells undergo cell cycle arrest, followed by induction of apoptosis, in response to KB528 treatment.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Table S12 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
MM primary patient RNA-seq samples at 12 hours DMSO, and post KB528.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S12 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
MM primary patient RNA-seq samples at 12 hours DMSO, and post KB528.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
Affinity purification – processed mass spectrometry data related to IRF4, p300, IKZF1, and IKZF3 within MM1.S.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
Affinity purification – processed mass spectrometry data related to IRF4, p300, IKZF1, and IKZF3 within MM1.S.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
EnhancerPromoter ChIP AUC output for IRF4, p300, and H3K27ac in MM1.S, as well as other omic metrics used for heatmap within Figure 3E.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
EnhancerPromoter ChIP AUC output for IRF4, p300, and H3K27ac in MM1.S, as well as other omic metrics used for heatmap within Figure 3E.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
Multiple myeloma transcriptional regulatory network (MM TRN) and each step used to create final network observed in Figure 1A.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
Multiple myeloma transcriptional regulatory network (MM TRN) and each step used to create final network observed in Figure 1A.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Table S9 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
GSEA results of RNA-seq analysis, and top bound IRF4/p300 genes. Data is used in Figure 3F and S3G.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
GSEA results of RNA-seq analysis, and top bound IRF4/p300 genes. Data is used in Figure 3F and S3G.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
Comparative pharmacology of KB528 treatment and other mechanisms of action in MM cells.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
Comparative pharmacology of KB528 treatment and other mechanisms of action in MM cells.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
Induction of cell cycle arrest and apoptosis in MM primary patient samples across treatment histories.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
Induction of cell cycle arrest and apoptosis in MM primary patient samples across treatment histories.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Table S10 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
RNA-seq time course data in combination with KB528, and other MM standard of care (SOC) compounds of interest
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
RNA-seq time course data in combination with KB528, and other MM standard of care (SOC) compounds of interest